Highest-materiality recent filing
Co-Diagnostics Q1 2026 revenue $0.15M; net loss $9.1M; advances India regulatory milestones
Revenue $0.15M vs $0.05M in Q1 2025; operating loss $9.2M vs $8.6M.
Co-Diagnostics FY2025 revenue drops 85% to $0.6M; net loss $46.9M; cash burn accelerates
Revenue fell to $0.6M from $3.9M in 2024; net loss was $46.9M ($35.25/share) vs $37.6M.
Co-Diagnostics regains Nasdaq compliance; preliminary cash $11.9M as of Dec 31, 2025
Nasdaq notified Co-Diagnostics (CODX) of compliance with $1.00 bid price rule; trading resumes March 11, 2026.
Co-Diagnostics receives Nasdaq delisting notice; trading to move to OTC Pink effective Jan 14
Nasdaq Staff determined to delist CODX due to continued non-compliance with minimum bid price rule.
Co-Diagnostics files 1-for-30 reverse stock split to regain Nasdaq minimum bid price compliance
Reverse stock split ratio set at 1-for-30; effective January 2, 2026 at 12:01 a.m. ET.
Co-Diagnostics shareholders approve reverse stock split up to 1-for-30
Special meeting on Dec 5, 2025 approved amendment for reverse stock split.
Revenue $0.1M, down from $0.6M YoY; net loss $5.9M ($0.16/share) vs $9.7M ($0.32) in Q3 2024.
Co-Diagnostics prices $7.0M registered direct offering of 12.7M shares at $0.55/share
Offering consists of 12,727,272 shares of common stock or pre-funded warrants at $0.55 per share.
New ATM allows sale of up to $10M in common stock through Maxim Group at market prices; 3.0% commission.
Co-Diagnostics announces $3.8M registered direct offering of 9.62M shares at $0.40/share
Sold 9,619,000 common shares at $0.40/share in registered direct offering to institutional investors.
Co-Diagnostics gets 180-day Nasdaq extension to meet $1 minimum bid rule
Additional 180-day grace period to regain compliance expires January 5, 2026.
Co-Diagnostics Q1 revenue $0.1M; net loss $7.5M; advancing platform pipeline
Revenue of $0.1M, down from $0.5M YoY due to no grant revenue recognized in Q1 2025.
Co-Diagnostics FY2024 revenue $3.9M, net loss $37.6M; withdraws 510(k) for platform
Revenue $3.9M vs $6.8M in 2023; product revenue $0.8M, grant revenue $3.1M.
Co-Diagnostics withdraws COVID-19 test 510(k) application; to submit enhanced version
Withdrew current 510(k) application for Co-Dx PCR COVID-19 Test after FDA feedback on component shelf-life stability.
Co-Diagnostics receives Nasdaq bid price deficiency notice; 180 days to regain compliance
Notice on Jan 10, 2025: closing bid price below $1.00 for 30 consecutive business days.
Co-Diagnostics Q3 revenue $0.6M down from $2.5M; net loss $9.7M ($0.32/share)
Q3 2024 revenue $0.6M ($0.4M grant + $0.2M product) vs $2.5M prior year, down 76%.
Co-Diagnostics Q2 revenue jumps to $2.7M, net loss narrows to $7.6M, submits 510(k) for PCR platform
Revenue of $2.7M vs $0.2M in prior year, driven by milestone achievements on grants.
Co-Diagnostics files first FDA 510(k) for Co-Dx PCR Pro platform and OTC COVID-19 test
FDA receives 510(k) submission for Co-Dx PCR Pro instrument and OTC COVID-19 test.
Co-Diagnostics Q1 net loss $9.3M ($0.31/share), revenue $0.5M, down 17% YoY
Revenue $0.5M ($0.3M product, $0.2M grant) vs $0.6M in Q1 2023.
On March 15, 2024, the Board of Directors of Co-Diagnostics, Inc. (the “Company”) appointed Richard Abbott as President.
Max materiality 0.85 · Median 0.65 · Most common event other_material